查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1579346

侵襲性纖維瘤病市場：按治療類型、分銷管道和最終用戶分類 - 全球預測 2025-2030

Aggressive Fibromatosis Market by Treatment Type (Non-Surgical Treatment, Surgical Treatment), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，侵襲性纖維瘤病市場估值為27.4億美元，預計2024年將達29億美元，複合年成長率為5.88%，到2030年將達41億美元。

侵襲性纖維瘤病，也稱為硬纖維瘤，是一種罕見的局部侵襲性腫瘤，由肌肉神經結構引起，並且不會轉移。侵襲性纖維瘤病市場範圍主要集中在有效治療方法的開拓、應用和商業化，重點是手術干預、藥物治療以及標靶治療和免疫治療等先進治療方法。由於術後復發和有效藥物治療有限，該疾病是一個臨床挑戰。除其他因素外，對新治療方法的需求是由於需要預防復發和控制發病率而不產生過度副作用。最終使用範圍主要針對患者尋求診斷和治療的醫院、專科診所和癌症治療中心。該市場的主要成長動力包括疾病意識的提高、診斷成像技術的進步以及對研發更有效治療方法的興趣日益濃厚。潛在的商機包括開發非侵入性治療方法、擴展到醫療需求未滿足的新興市場以及利用生物技術的創新藥物輸送系統。然而，治療成本上升、疾病的罕見性可能限制市場規模以及給新參與企業帶來挑戰的監管障礙等限制因素。罕見疾病研究的資金籌措限制進一步影響成長前景。分子遺傳學的針對性研究、新藥配方的穩健臨床試驗以及全球機構之間共用知識的合作研究為創新和業務成長提供了可行的途徑。儘管該市場是利基市場，但成長是由癌症研究的技術進步和孤兒藥研發的策略重點所推動的。簡而言之，對研究的大量投資，加上對教育和患者支持的策略重點，可能會顯著增強市場活力。

主要市場統計
基準年[2023] 27.4億美元
預測年份 [2024] 29億美元
預測年份 [2030] 41億美元
複合年成長率（%） 5.88%

市場動態：針對快速發展的侵襲性纖維瘤病市場揭示的關鍵市場洞察

供需的動態交互作用正在改變積極的纖維瘤病市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 提高醫療保健提供者的意識並提高侵襲性纖維瘤病的診斷準確性
    • 監管支持和孤兒藥指定，以加速罕見疾病治療的開發
    • 擴大製藥公司、研究機構和學術中心之間的合作和夥伴關係，加速新治療方法的開發
  • 市場限制因素
    • 開發和銷售新治療方法，尤其是針對特定疾病
  • 市場機會
    • 關於侵襲性纖維瘤病遺傳和分子基礎的醫學研究和技術進展
    • 整合遠端醫療、行動醫療應用程式和穿戴式裝置等數位健康技術，以監測治療反應和患者依從性
  • 市場挑戰
    • 侵襲性纖維瘤病的治療選擇和標靶治療有限

波特的五力：駕馭激進的纖維瘤市場的策略工具

波特的五力架構是了解侵襲性纖維瘤病市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解侵襲性纖維瘤市場的外部影響

外部宏觀環境因素在塑造侵襲性纖維瘤病市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解激進的纖維瘤市場的競爭格局

對侵襲性纖維瘤病市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣侵襲性纖維瘤病市場供應商的績效評估

FPNV 定位矩陣是評估侵襲性纖維瘤市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了侵襲性纖維瘤病市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對侵襲性纖維瘤病市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高醫護人員的認知並更準確地診斷侵襲性纖維瘤病
      • 監管支持和孤兒藥指定，以加速罕見疾病治療方法的開發
      • 擴大製藥公司、研究機構和學術中心之間的合作和夥伴關係，加速新治療方法的開發
    • 抑制因素
      • 開發新治療方法並將其推向市場需要高昂的研發成本，尤其是針對小眾疾病。
    • 機會
      • 關於侵襲性纖維瘤病遺傳和分子基礎的醫學研究和技術進展
      • 整合遠端醫療、行動醫療應用程式和穿戴式裝置等數位健康技術，以監測治療反應和患者依從性
    • 任務
      • 侵襲性纖維瘤病的治療選擇和標靶治療有限
  • 市場區隔分析
    • 治療類型：非手術治療因其侵入性較小而越來越受青睞
    • 最終用戶：對門診手術中心提供微創手術的需求日益成長。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的侵襲性纖維瘤病市場

  • 非手術治療
    • 冷凍療法
    • 藥物治療
    • 放射治療
    • 射頻消融術
  • 手術治療
    • 保守手術
    • 根治性切除手術

第7章 激進的纖維瘤市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第 8 章 激進的纖維瘤病市場：按最終用戶

  • 門診手術中心
  • 醫院
  • 研究/學術機構
  • 專科診所

第9章美洲激進的纖維瘤病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區侵襲性纖維瘤病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 11 章：歐洲、中東和非洲激進的纖維瘤市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 根據 3 期 DeFi 試驗的結果，歐洲藥品管理局已核准SpringWorks Therapeutics 的 nirogacestat 申請，這是一種針對硬纖維瘤的突破性治療方法。
    • SpringWorks Therapeutics 的 nirogacestat MAA 已獲得 EMA核准，為歐盟核准的首個硬纖維瘤治療方法鋪平了道路，3 期試驗結果顯示出顯著的臨床益處。
    • Immunome 以 5,000 萬美元從 Ayala Pharmaceuticals 收購了 3 期伽馬分泌酶抑制劑 AL102，以加強其癌症治療組合和臨床結果。
  • 戰略分析和建議

公司名單

  • 4D Molecular Therapeutics
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurinia Pharmaceuticals Inc.
  • Bayer AG
  • Bioporto Diagnostics A/S
  • Boston Scientific Corporation
  • Celgene Corporation（a Bristol-Myers Squibb Company）
  • Eli Lilly and Company
  • Epizyme, Inc.
  • Exelixis, Inc.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Ltd.
  • Infinity Pharmaceuticals, Inc.
  • Johnson & Johnson Service, Inc.
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Oncoheroes Biosciences Inc.
  • Pfizer Inc.
  • Sanofi SA
  • SpringWorks Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-8D2A8051067F

The Aggressive Fibromatosis Market was valued at USD 2.74 billion in 2023, expected to reach USD 2.90 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 4.10 billion by 2030.

Aggressive fibromatosis, also known as desmoid tumors, is a rare type of locally invasive tumor which arises from the musculo-aponeurotic structures and does not metastasize. The market scope for aggressive fibromatosis primarily revolves around the development, application, and commercialization of effective therapies, emphasizing surgical interventions, pharmacological treatments, and advanced therapeutic approaches such as targeted therapy and immunotherapy. This condition notoriously poses a clinical challenge given its recurrence post-surgery and limited effective pharmacotherapy. The necessity for novel treatment regimens can be particularly attributed to the need to prevent recurrence and manage morbidity without excessive adverse effects. The end-use scope primarily targets hospitals, specialty clinics, and cancer treatment centers where patients seek diagnosis and treatment. Key growth drivers in this market include heightened awareness about the condition, advancements in diagnostic imaging techniques, and the increasing interest in research and development for more effective therapeutic methods. Potential opportunities lie in developing non-invasive therapies, expanding into emerging markets with unmet medical needs, and leveraging biotechnology for innovative drug delivery systems. Nonetheless, the market faces limitations such as high treatment costs, the rarity of the condition which may limit market size, and regulatory hurdles which pose challenges to new market entrants. Funding constraints for research into rare diseases further impact growth prospects. For innovation and business growth, targeted research in molecular genetics, robust clinical trials for novel drug formulations, and collaborations for knowledge sharing among global institutions offer viable pathways. The market is largely niche but poised for growth driven by technological advances in oncology research and a strategic focus on orphan drug development. In essence, substantial investment in research, coupled with a strategic focus on education and patient advocacy, could significantly enhance market dynamics.

KEY MARKET STATISTICS
Base Year [2023] USD 2.74 billion
Estimated Year [2024] USD 2.90 billion
Forecast Year [2030] USD 4.10 billion
CAGR (%) 5.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Aggressive Fibromatosis Market

The Aggressive Fibromatosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising awareness among healthcare providers and more accurate diagnosis of aggressive fibromatosis
    • Regulatory support and orphan drug designations encouraging the development of treatments for rare diseases
    • Growing collaboration and partnerships between pharmaceutical companies, research institutions, and academic centers to accelerate the development of new treatments
  • Market Restraints
    • High R&D Costs required to develop and bring new therapies to market particularly for niche conditions
  • Market Opportunities
    • Advances in medical research and technology of the genetic and molecular basis of aggressive fibromatosis
    • Integration in digital health technologies such as telemedicine, mobile health apps, and wearable devices for monitoring treatment response and patient adherence
  • Market Challenges
    • Limited treatment options and targeted therapies for aggressive fibromatosis

Porter's Five Forces: A Strategic Tool for Navigating the Aggressive Fibromatosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Aggressive Fibromatosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Aggressive Fibromatosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Aggressive Fibromatosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Aggressive Fibromatosis Market

A detailed market share analysis in the Aggressive Fibromatosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Aggressive Fibromatosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Aggressive Fibromatosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Aggressive Fibromatosis Market

A strategic analysis of the Aggressive Fibromatosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Aggressive Fibromatosis Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, AbbVie Inc., Amgen Inc., AstraZeneca plc, Aurinia Pharmaceuticals Inc., Bayer AG, Bioporto Diagnostics A/S, Boston Scientific Corporation, Celgene Corporation (a Bristol-Myers Squibb Company), Eli Lilly and Company, Epizyme, Inc., Exelixis, Inc., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Infinity Pharmaceuticals, Inc., Johnson & Johnson Service, Inc., Medtronic plc, Merck & Co., Inc., Novartis AG, Oncoheroes Biosciences Inc., Pfizer Inc., Sanofi S.A., SpringWorks Therapeutics, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Aggressive Fibromatosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Non-Surgical Treatment and Surgical Treatment. The Non-Surgical Treatment is further studied across Cryoablation, Pharmacological Therapies, Radiation Therapy, and Radiofrequency Ablation. The Surgical Treatment is further studied across Conservative surgery and Radical resection.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, Research & Academic Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising awareness among healthcare providers and more accurate diagnosis of aggressive fibromatosis
      • 5.1.1.2. Regulatory support and orphan drug designations encouraging the development of treatments for rare diseases
      • 5.1.1.3. Growing collaboration and partnerships between pharmaceutical companies, research institutions, and academic centers to accelerate the development of new treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High R&D Costs required to develop and bring new therapies to market particularly for niche conditions
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in medical research and technology of the genetic and molecular basis of aggressive fibromatosis
      • 5.1.3.2. Integration in digital health technologies such as telemedicine, mobile health apps, and wearable devices for monitoring treatment response and patient adherence
    • 5.1.4. Challenges
      • 5.1.4.1. Limited treatment options and targeted therapies for aggressive fibromatosis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Growing preference for non-surgical treatments owing to their minimally invasive nature
    • 5.2.2. End User: Increasing need for ambulatory surgical centers offering minimally invasive surgical interventions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Aggressive Fibromatosis Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Non-Surgical Treatment
    • 6.2.1. Cryoablation
    • 6.2.2. Pharmacological Therapies
    • 6.2.3. Radiation Therapy
    • 6.2.4. Radiofrequency Ablation
  • 6.3. Surgical Treatment
    • 6.3.1. Conservative surgery
    • 6.3.2. Radical resection

7. Aggressive Fibromatosis Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Aggressive Fibromatosis Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Research & Academic Institutes
  • 8.5. Specialty Clinics

9. Americas Aggressive Fibromatosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Aggressive Fibromatosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Aggressive Fibromatosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. European Medicines Agency validates SpringWorks Therapeutics' application for nirogacestat, a groundbreaking treatment for desmoid tumors, following phase 3 DeFi trial results
    • 12.3.2. SpringWorks Therapeutics' nirogacestat MAA accepted by EMA, paving the way for first EU-approved therapy for desmoid tumors, showcasing significant clinical benefits from Phase 3 trial outcomes
    • 12.3.3. Immunome acquires Phase 3 gamma secretase inhibitor AL102 from Ayala for $50M to enhance cancer therapy portfolio and clinical outcomes
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Molecular Therapeutics
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca plc
  • 5. Aurinia Pharmaceuticals Inc.
  • 6. Bayer AG
  • 7. Bioporto Diagnostics A/S
  • 8. Boston Scientific Corporation
  • 9. Celgene Corporation (a Bristol-Myers Squibb Company)
  • 10. Eli Lilly and Company
  • 11. Epizyme, Inc.
  • 12. Exelixis, Inc.
  • 13. GlaxoSmithKline plc
  • 14. Hoffmann-La Roche Ltd.
  • 15. Infinity Pharmaceuticals, Inc.
  • 16. Johnson & Johnson Service, Inc.
  • 17. Medtronic plc
  • 18. Merck & Co., Inc.
  • 19. Novartis AG
  • 20. Oncoheroes Biosciences Inc.
  • 21. Pfizer Inc.
  • 22. Sanofi S.A.
  • 23. SpringWorks Therapeutics, Inc.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. AGGRESSIVE FIBROMATOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. AGGRESSIVE FIBROMATOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AGGRESSIVE FIBROMATOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AGGRESSIVE FIBROMATOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AGGRESSIVE FIBROMATOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AGGRESSIVE FIBROMATOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY CONSERVATIVE SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RADICAL RESECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. AGGRESSIVE FIBROMATOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. AGGRESSIVE FIBROMATOSIS MARKET, FPNV POSITIONING MATRIX, 2023